Potential targets of glucagon-like peptide 1 receptor agonist ticagrelor in the treatment of Alzheimer’s disease

• Ticagrelor, a GLP-1 receptor agonist, shows potential in treating Alzheimer's disease by targeting AGTR2. • Network pharmacology identified 10 key genes, including AGTR2, as potential mediators of ticagrelor's effects. • In vitro and in vivo experiments confirmed that ticagrelor improves synaptic function and reduces AD pathology. • Ticagrelor ameliorates cognitive deficits and reduces β-amyloid deposition and Tau phosphorylation in 3xTg mice.